Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J chief hints at unease in China, but plots new buyouts

Johnson & Johnson CEO Alex Gorsky likes to hint at trouble developing its Chinese sales, but don't expect him to come right out and criticize the prickly Chinese government. In an brief interview with The Wall Street Journal, Gorsky said J&J was looking for new acquisitions in China, with new drugs for lung cancer as one of its topic targets.

Can J&J score sales with FDA's new Olysio-plus-Sovaldi approval?

Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA approval as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. The question now is how much that approval will help Olysio withstand competition, both current and forthcoming.

New numbers back old meme: Pharma does spend more on marketing than R&D

The BBC has some numbers sourced from GlobalData showing that 9 out of 10 Big Pharma companies do in fact spend more on marketing than on R&D. In some cases, that's twice as much.

J&J, Pfizer, Novartis are the in-demand pharmas among job-seekers, LinkedIn says

Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it's always nice to know that would-be job seekers think your company is swell. Here's the latest gauge of drugmakers' status in the world of recruiting.

Report: GSK, J&J, Merck and Sanofi have made mobile app breakthroughs

A report by Research2Guidance found that GlaxoSmithKline, Johnson & Johnson, Merck and Sanofi outperformed their peers in terms of apps downloaded.

Johnson & Johnson weighs $250M settlement to resolve more hip implant claims

Long plagued by suits over its metal-on-metal hip implants, Johnson & Johnson is weighing a $250 million settlement to resolve more claims that were not covered under an earlier accord.

J&J partnering team now embedded in Shanghai hub, completing global network

J&J is officially cutting the ribbon on its new partnering office in Shanghai, completing the pharma giant's global plan to hit the ground running in all the world's top biotech hot spots. It's taking the wraps off of a lineup of new discovery deals with universities in the region. And it's spreading out feelers for more deals through satellite offices in Australia, Singapore and Japan.

J&J scores victory in first metal-on-metal hip implant case to go to trial

Johnson & Johnson scored a victory in the first case to go to trial for its metal-on-metal hip implants, as a Texas jury ruled against a woman who claimed that Pinnacle devices made by the company's DePuy subsidiary poisoned her and caused undue pain and suffering.

J&J Innovation taps Texas for its latest biotech startup incubator

Johnson & Johnson taking its network of biopharma incubators to Texas in an expansion of its Janssen Labs initiative.

J&J prepares to face ruling in first Pinnacle hip implant trial

Johnson & Johnson is facing grave allegations that the company, in an effort to preserve billions in profit, ignored overwhelming evidence that its Pinnacle hip implants were highly dangerous.